Skip to Content
Søg Menu

ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer

At ESMO 2024, the 3-year results from the KEYNOTE-A18 study were presented, showing a clinically meaningful benefit of adding immunotherapy to the treatment regimen.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Urgent Need for More Knowledge About Quality of Life and Symptoms in Cancer Patients over 80 Years of Age

/ Elisabeth Grov Beisland
ESMO24 Play the Video 02:13

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Henrik Grönberg
ESMO24Prostatacancer Play the Video 02:35
Ingrid Dyvik

The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

/ Ingrid Dyvik
ESMO24 Play the Video 3:00
Jørgen Bjerggaard Jensen

ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

/ Jørgen Bjerggaard Jensen
ESMO24Blærecancer Play the Video 03:39
Louise Wichmann Matthiessen

Nye positive resultater for behandling af brystcancer fremlagt på ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video 03:02
Bjørn H. Grønberg

Høydepunkter fra ESMO 2024 om lungekreft

/ Bjørn Henning Grønberg
ESMO24Lungecancer Play the Video 3:56
Claus Andrup Kristensen

LBA35: Positive Efficacy for Eftilagimod plus Pembrolizumab in Patients with Head and Neck Squamous Cell Carcinoma

/ Claus Andrup Kristensen
ESMO24 Play the Video 02:43
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
ESMO24ProstatacancerNyrecancerBlærecancer Play the Video 4:25
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
ESMO24Brystcancer Play the Video 04:50

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top